Address correspondence to Dr Theresa A. Zesiewicz, University of South Florida, 12901 Bruce B. Downs Blvd, MDC Box 55, Tampa, FL 33612, [email protected].
RELATIONSHIP DISCLOSURE: Dr Zesiewicz has received personal compensation for serving on the advisory boards of Boston Scientific; Reata Pharmaceuticals, Inc; and Steminent Biotherapeutics. Dr Zesiewicz has received personal compensation as senior editor for Neurodegenerative Disease Management and as a consultant for Steminent Biotherapeutics. Dr Zesiewicz has received royalty payments as co-inventor of varenicline for treating imbalance (patent number 9,463,190) and nonataxic imbalance (patent number 9,782,404). Dr Zesiewicz has received research/grant support as principal investigator/investigator for studies from AbbVie Inc; Biogen; Biohaven Pharmaceutics; Boston Scientific; Bukwang Pharmaceuticals Co, Ltd; Cala Health, Inc; Cavion; Friedreich’s Ataxia Research Alliance; Houston Methodist Research Institute; National Institutes of Health (READISCA U01); Retrotope Inc; and Takeda Development Center Americas, Inc.
UNLABELED USE OF PRODUCTS/INVESTIGATIONAL USE DISCLOSURE: Dr Zesiewicz reports no disclosure.